Treatment with antipsychotic drugs and levodopa (commonly used to treat Parkinson disease) are well recognized causes of drug-induced dyskinesia. Several Drosophila models have been developed to investigate levodopa-induced dyskinesia (LID). Larval locomotion patterns and atypical phenotypes have been used to assess effects of L-DOPA and rescue by a dopamine agonist. In order to develop a model of such drug-induced dyskinesia in adult flies, three components in fly locomotion -- speed, yawing and freezing -- have been assessed. Prolonged L-DOPA treatment results in elevated instances of levodopa-induced dyskinesia-like phenotypes in Parkinson disease model flies; acute L-DOPA treatment improves the motor defects of the flies with no dyskinesia-like phenotypes. This model has been used to identify genes involved in development of levodopa-induced dyskinesia; variants in these genes may result in susceptibility to LID.
See also the FlyBase chemical report for L-dopa (FBch0000146).
[updated Mar. 2024 by FlyBase; FBrf0222196]
Drug induced dyskinesia is an involuntary movement disorder. Signs and symptoms include repetitive and irregular motions of the mouth, face, limbs and/or trunk. Treatment with antipsychotic drugs and levodopa (commonly used to treat Parkinson disease) are well recognized causes of drug-induced dyskinesia. Tardive dyskinesia is a severe form of drug-induced dyskinesia due to antipsychotic treatments (GARD, Drug induced dyskinesia; 2022.11.07; https://rarediseases.info.nih.gov/diseases/8236/drug-induced-dyskinesia).
